U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H36F2O6
Molecular Weight 482.5572
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of SEPETAPROST

SMILES

[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)COC3=C(F)C=CC(F)=C3)[C@@]1([H])CC[C@H](CCCC(=O)OC(C)C)CO2

InChI

InChIKey=BKVUSNOUTQMSBE-XCMGCKIWSA-N
InChI=1S/C26H36F2O6/c1-16(2)34-26(31)5-3-4-17-6-9-21-20(23(30)13-24(21)32-14-17)10-8-19(29)15-33-25-12-18(27)7-11-22(25)28/h7-8,10-12,16-17,19-21,23-24,29-30H,3-6,9,13-15H2,1-2H3/b10-8+/t17-,19+,20+,21+,23+,24-/m0/s1

HIDE SMILES / InChI

Molecular Formula C26H36F2O6
Molecular Weight 482.5572
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 1
Optical Activity UNSPECIFIED

Sepetoprost (also known as ONO-9054), prostaglandin analog was developed as a dual agonist of prostaglandin E3 (EP3) and prostaglandin F (FP) receptors. It is known, that the use of a dual prostaglandin EP3 and prostaglandin F receptor agonists is a novel approach for the reduction of intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Sepetoprost was successfully studied in clinical trials phase II for the treatment of open-angle glaucoma, ocular hypertension, and mild open angle-glaucoma.

Approval Year

PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Nine subjects were randomized to each of ONO-9054 (sepetaprost) 3, 10, 20, 30 μg/mL and 12 to placebo. Subjects received a single drop to each eye at 07:00±30 minutes (single dose). Following a 4-day no-treatment period, subjects were dosed once daily for 14 consecutive days (multiple day dosing)
Route of Administration: Other
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:47:05 GMT 2023
Edited
by admin
on Sat Dec 16 09:47:05 GMT 2023
Record UNII
79O7855J4G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SEPETAPROST
INN   WHO-DD  
INN  
Official Name English
DE-126
Code English
2H-CYCLOPENT(B)OXEPIN-3-BUTANOIC ACID, 6-((1E,3R)-4-(2,5-DIFLUOROPHENOXY)-3-HYDROXY-1-BUTEN-1-YL)OCTAHYDRO-7-HYDROXY-, 1-METHYLETHYL ESTER, (3S,5AR,6R,7R,8AS)-
Systematic Name English
ONO-9054
Code English
2-PROPANYL 4-((3S,5AR,6R,7R,8AS)-6-((1E,3R)-4-(2,5-DIFLUOROPHENOXY)-3-HYDROXY-1-BUTEN-1-7-HYDROXYOCTAHYDRO-2H-CYCLOPENTA(B)OXEPIN-3-YL)BUTANOATE
Systematic Name English
STN-1012600
Code English
Sepetaprost [WHO-DD]
Common Name English
STN1012600
Code English
sepetaprost [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29705
Created by admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
NCI_THESAURUS C78568
Created by admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
Code System Code Type Description
CLINICAL_TRIALS.GOV
SEPETAPROST
Created by admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
PRIMARY The primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (IOP) of ONO-9054 30 ?g/mL (0.003%) to latanoprost 0.005% following ocular instillation once every evening for 28 days.
SMS_ID
300000031915
Created by admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
PRIMARY
FDA UNII
79O7855J4G
Created by admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
PRIMARY
INN
9850
Created by admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
PRIMARY
NCI_THESAURUS
C152337
Created by admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
PRIMARY
PUBCHEM
50902259
Created by admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
PRIMARY
CAS
1262873-06-2
Created by admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
PRIMARY
DRUG BANK
DB12043
Created by admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
PRIMARY
Related Record Type Details
TARGET->WEAK AGONIST
EC50
TARGET->WEAK AGONIST
Prodrug becomes agonist upon cleavage
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG